JP2025509976A5 - - Google Patents

Info

Publication number
JP2025509976A5
JP2025509976A5 JP2024556159A JP2024556159A JP2025509976A5 JP 2025509976 A5 JP2025509976 A5 JP 2025509976A5 JP 2024556159 A JP2024556159 A JP 2024556159A JP 2024556159 A JP2024556159 A JP 2024556159A JP 2025509976 A5 JP2025509976 A5 JP 2025509976A5
Authority
JP
Japan
Prior art keywords
antisense oligonucleotide
nucleotides
pharmaceutical composition
composition according
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556159A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509976A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2023/050213 external-priority patent/WO2023178386A1/en
Publication of JP2025509976A publication Critical patent/JP2025509976A/ja
Publication of JP2025509976A5 publication Critical patent/JP2025509976A5/ja
Pending legal-status Critical Current

Links

JP2024556159A 2022-03-23 2023-03-23 緑内障の処置方法 Pending JP2025509976A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2022900727A AU2022900727A0 (en) 2022-03-23 Methods of treating glaucoma
AU2022900727 2022-03-23
PCT/AU2023/050213 WO2023178386A1 (en) 2022-03-23 2023-03-23 Methods of treating glaucoma

Publications (2)

Publication Number Publication Date
JP2025509976A JP2025509976A (ja) 2025-04-11
JP2025509976A5 true JP2025509976A5 (cg-RX-API-DMAC7.html) 2026-03-31

Family

ID=88099395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556159A Pending JP2025509976A (ja) 2022-03-23 2023-03-23 緑内障の処置方法

Country Status (9)

Country Link
US (1) US20250179490A1 (cg-RX-API-DMAC7.html)
EP (1) EP4496892A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509976A (cg-RX-API-DMAC7.html)
KR (1) KR20240165951A (cg-RX-API-DMAC7.html)
CN (1) CN119053704A (cg-RX-API-DMAC7.html)
AU (1) AU2023237229A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246175A1 (cg-RX-API-DMAC7.html)
IL (1) IL315133A (cg-RX-API-DMAC7.html)
WO (1) WO2023178386A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12338437B2 (en) 2020-05-11 2025-06-24 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
WO2024221049A1 (en) * 2023-04-28 2024-10-31 PYC Therapeutics Limited Agents and method of treatment for optic conditions
WO2025240992A1 (en) * 2024-05-24 2025-11-27 PYC Therapeutics Limited Agents for treatment of conditions associated with optic atrophy 1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
EP3286318A2 (en) * 2015-04-22 2018-02-28 Mina Therapeutics Limited Sarna compositions and methods of use
US12338437B2 (en) * 2020-05-11 2025-06-24 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
EP4222265A4 (en) * 2020-10-02 2025-07-16 Pyc Therapeutics Ltd TREATMENT OF OPTIC ATROPHY
JP7811941B2 (ja) * 2020-10-08 2026-02-06 フォンダツィオーネ・イスティテュート・イタリアーノ・ディ・テクノロジア 機能性核酸分子

Similar Documents

Publication Publication Date Title
KR102095699B1 (ko) 트랜스티레틴(TTR) 관련 질병을 치료하기 위한 RNAi 제제, 조성 및 그의 사용방법
TWI727963B (zh) 甲狀腺素運載蛋白(TTR)iRNA組成物及其治療或預防TTR相關疾病之使用方法
ES2649817T3 (es) Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
TW201639961A (zh) 含類馬鈴薯儲藏蛋白磷脂酶域3(PNPLA3)iRNA組成物及其使用方法
TW201631156A (zh) B型肝炎病毒(HBV)iRNA組成物及其用途方法
CA2163234A1 (en) Inhibition of proliferation of vascular smooth muscle cell
JP2022501057A (ja) トランスサイレチン(TTR)iRNA組成物及びTTR関連眼疾患を治療又は予防するためのその使用方法
JP2008514647A (ja) 二本鎖リボ核酸によって炎症性疾患を治療する方法
AU2006311912A1 (en) Peptide-dicer substrate RNA conjugates as delivery vehicles for siRNA
US10933081B2 (en) Myostatin iRNA compositions and methods of use thereof
TW202400792A (zh) 用於抑制mapt表現之組合物及方法
TW202411427A (zh) 用於抑制細胞中agt表現之核酸
JP2024514880A (ja) Pnpla3発現を調節するための組成物及び方法
KR20250125967A (ko) 진보된 rna 표적화 (arnatar)
JP2022530678A (ja) 短縮センス鎖を有する二本鎖核酸阻害剤分子
CA3094008A1 (en) Double-stranded nucleic acid inhibitor molecules modified with tm-increasing nucleotides
KR102701681B1 (ko) 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19〔covid-19〕치료용 조성물
EP4562158A1 (en) Advanced rna targeting (arnatar) for angiotensinogen
WO2026064538A2 (en) Advanced rna targeting (arnatar) for inhbe
US20230416743A1 (en) Compositions and methods for inhibiting snca expression
WO2022092279A1 (ja) siRNA及び医薬組成物並びに予防及び/又は治療剤
RU2024126206A (ru) Способы лечения глаукомы
RU2804776C2 (ru) СРЕДСТВА ДЛЯ РНКи, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, АССОЦИИРОВАННЫХ С ТРАНСТИРЕТИНОМ (TTR)
TW202345873A (zh) 調節scap活性之組合物及方法
WO2024255749A1 (zh) 靶向血管紧张素原的核酸及其用途